zinc finger protein 861, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF861P profile across patient tissues and cancer cell-line models. ZNF861P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ZNF861P is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, ZNF861P RNA expression shows 6,741 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, BLCA, and STAD as cancer lineages where ZNF861P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF861P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF861P survival associations across molecular data types. ZNF861P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF861P RNA expression–survival associations across cancer types. High ZNF861P expression shows unfavorable associations in THCA, TGCT, READ, KICH and THYM, but favorable associations in LAML. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ZNF861P RNA expression.
This table summarizes ZNF861P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF861P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF861P shows lower tumor expression in THCA and higher tumor expression in BLCA, READ and LUAD. The BLCA box plot shows higher ZNF861P RNA expression in tumor versus normal tissue (log2 FC = +0.251, t-test p = .006).
This table shows molecular features associated with ZNF861P in patient tissues and cancer cell lines. In patient samples, ZNF861P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
